Jennifer Brown
PhD, MAS
Visiting Postdoctoral Researcher
My research focuses on HIV with emphasis on HIV drug resistance, the rollout of new antiretrovirals, and paediatric HIV. After previously working on randomised clinical trials and cohorts in Lesotho and Tanzania, I am now turning towards causal inference from large observational datasets in South Africa and the UK. Specifically, I aim to compare various paediatric and adult first- and second-line treatments, different modalities for community treatment pick-up, as well as investigating cardiovascular disease in people with HIV.
I am currently dividing my time between the Infection, Respiratory and Acute Care (IRAC) group in Oxford and the Centre for the AIDS Programme of Research in South Africa (CAPRISA). Before this, I was based in Switzerland working with the Division of Clinical Epidemiology at the University of Basel, where I ran the GIVE MOVE trial assessing genotypic resistance testing to inform care for children and adolescents with failing antiretroviral therapy, the LoDoCA cohort on the rollout of paediatric dolutegravir, and assessed emerging dolutegravir resistance within the VICONEL cohort.
I am funded by a Postdoc.Mobility grant from the Swiss National Science Foundation and have previously received funding from the University of Basel Research Fund and Fondation Botnar.
Previous Experience and Education
Since 04/2024 – Postdoctoral Fellow, University of Oxford / CAPRISA
08/2022 - 03/2024 – Postdoc / Project Leader, University Hospital Basel
01/2022 - 07/2022 – Postdoctoral Scientific Collaborator, Swiss Tropical and Public Health Institute
03/2018 - 12/2021 – PhD in Medical Biological Research, University of Basel
02/2017 - 11/2017 – Project Assistant Molecular HIV Diagnostics, Swiss Tropical and Public Health Institute
09/2016 - 06/2019 – MAS in Development and Cooperation, ETH Zurich
09/2014 - 10/2016 – MSc in Biology (specialisation Cell Biology), ETH Zurich
09/2011 - 09/2014 – BSc in Biology, ETH Zurich
Key publications
-
Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial
Brown JA. et al, (2025)
Recent publications
-
Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa
Dorward J. et al, (2025)
-
Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial
Brown JA. et al, (2025)
-
Cohort profile: the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2023 – cohort description, test volumes, predictors of viraemia and the road ahead
Brown JA. et al, (2025), BMJ Open, 15, e085404 - e085404
-
Hair salons as a promising space to provide HIV and sexual and reproductive health services for young women in Lesotho: A citizen scientist mixed-methods study
Chiaborelli M. et al, (2024)
-
Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho
Tschumi N. et al, (2024), Clinical Infectious Diseases, 79, 1208 - 1222